Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.

BMC medical genetics - 29 Dec 2013

Heitzer Ellen, Lax Sigurd, Lafer Ingrid, Müller Stephanie M, Pristauz Gunda, Ulz Peter, Jahn Stephan, Högenauer Christoph, Petru Edgar, Speicher Michael R, Geigl Jochen B

Abstract excerpt

BACKGROUND: Germline genetic testing for familial cancer syndromes is usually performed serially for the most likely genetic causes. In recent years the way genetic testing carried out has changed, as next generation sequencing now allows the simultaneous testing of multiple susceptibility genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antigens, CD

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cadherins

Share to Endometrial Neoplasms

Share to Genetic Testing

Share to Pedigree

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 24373500
DOI: 10.1186/1471-2350-14-129
PMCID: PMC3913615

Genes

CDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24373500-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.PMID 24373500Read ↗

Double heterozygous pathogenic variants prevalence in a cohort of patients with hereditary breast cancerSemantic proximity Read ↗

Concurrent pathogenic variations in patients with hereditary cancer syndromes.Semantic proximity Read ↗

Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?Semantic proximity Read ↗

Molecular genetic investigation of hereditary breast and ovarian cancer patients in the Southern Transdanubian region: widening the mutation spectrum and searching for new pathogenic variants using next-generation methods.Semantic proximity Read ↗

Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.Semantic proximity Read ↗

Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.Semantic proximity Read ↗

Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.Semantic proximity Read ↗

Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family.Semantic proximity Read ↗

Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer: a case reportSemantic proximity Read ↗

Hereditary Cancer Syndrome in a Family with Double Mutation in BRIP1 and MUTYH Genes.Semantic proximity Read ↗

Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors.Semantic proximity Read ↗

Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.